These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15678362)

  • 1. Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys.
    Spinelli S; Ballard T; Gatti-McArthur S; Richards GJ; Kapps M; Woltering T; Wichmann J; Stadler H; Feldon J; Pryce CR
    Psychopharmacology (Berl); 2005 Apr; 179(1):292-302. PubMed ID: 15678362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing effects of nicotine and impairing effects of scopolamine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys.
    Spinelli S; Ballard T; Feldon J; Higgins GA; Pryce CR
    Neuropharmacology; 2006 Aug; 51(2):238-50. PubMed ID: 16678864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
    Krystal JH; Abi-Saab W; Perry E; D'Souza DC; Liu N; Gueorguieva R; McDougall L; Hunsberger T; Belger A; Levine L; Breier A
    Psychopharmacology (Berl); 2005 Apr; 179(1):303-9. PubMed ID: 15309376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
    Schlumberger C; Schäfer D; Barberi C; Morè L; Nagel J; Pietraszek M; Schmidt WJ; Danysz W
    Behav Pharmacol; 2009 Feb; 20(1):56-66. PubMed ID: 19179851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2/3 agonist LY354740.
    Procaccini C; Maksimovic M; Aitta-Aho T; Korpi ER; Linden AM
    Neuroscience; 2013 Oct; 250():189-200. PubMed ID: 23867766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of the marmoset monkey on computerized tasks of attention and working memory.
    Spinelli S; Pennanen L; Dettling AC; Feldon J; Higgins GA; Pryce CR
    Brain Res Cogn Brain Res; 2004 Apr; 19(2):123-37. PubMed ID: 15019709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
    Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
    Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The group II metabotropic glutamate receptor agonist LY354740 and the D2 receptor antagonist haloperidol reduce locomotor hyperactivity but fail to rescue spatial working memory in GluA1 knockout mice.
    Boerner T; Bygrave AM; Chen J; Fernando A; Jackson S; Barkus C; Sprengel R; Seeburg PH; Harrison PJ; Gilmour G; Bannerman DM; Sanderson DJ
    Eur J Neurosci; 2017 Apr; 45(7):912-921. PubMed ID: 28186680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
    J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans.
    Grillon C; Cordova J; Levine LR; Morgan CA
    Psychopharmacology (Berl); 2003 Aug; 168(4):446-54. PubMed ID: 12709777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
    Cartmell J; Monn JA; Schoepp DD
    J Pharmacol Exp Ther; 1999 Oct; 291(1):161-70. PubMed ID: 10490900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Group II selective metabotropic glutamate receptor agonists and local cerebral glucose use in the rat.
    Lam AG; Monn JA; Schoepp DD; Lodge D; McCulloch J
    J Cereb Blood Flow Metab; 1999 Oct; 19(10):1083-91. PubMed ID: 10532632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the group II metabotropic glutamate receptor agonist, LY354740 on schedule-controlled behaviour in rats.
    Moore NA; Rees G; Monn JA
    Behav Pharmacol; 1999 May; 10(3):319-25. PubMed ID: 10780246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia.
    Bond A; O'Neill MJ; Hicks CA; Monn JA; Lodge D
    Neuroreport; 1998 Apr; 9(6):1191-3. PubMed ID: 9601692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats.
    Konieczny J; Ossowska K; Wolfarth S; Pilc A
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Oct; 358(4):500-2. PubMed ID: 9826074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia.
    Lam AG; Soriano MA; Monn JA; Schoepp DD; Lodge D; McCulloch J
    Neurosci Lett; 1998 Sep; 254(2):121-3. PubMed ID: 9779935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in Rats.
    Ahnaou A; Lavreysen H; Tresadern G; Cid JM; Drinkenburg WH
    PLoS One; 2015; 10(12):e0144017. PubMed ID: 26658273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel orally active group 2 metabotropic glutamate receptor agonist: LY354740.
    Bond A; Monn JA; Lodge D
    Neuroreport; 1997 Apr; 8(6):1463-6. PubMed ID: 9172154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists.
    Woltering TJ; Wichmann J; Goetschi E; Knoflach F; Ballard TM; Huwyler J; Gatti S
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6969-74. PubMed ID: 20971004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct properties of presynaptic group II and III metabotropic glutamate receptor-mediated inhibition of perforant pathway-CA1 EPSCs.
    Capogna M
    Eur J Neurosci; 2004 May; 19(10):2847-58. PubMed ID: 15147318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.